0001599298-24-000046.txt : 20240327
0001599298-24-000046.hdr.sgml : 20240327
20240327202703
ACCESSION NUMBER: 0001599298-24-000046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240326
FILED AS OF DATE: 20240327
DATE AS OF CHANGE: 20240327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dhingra Ankur
CENTRAL INDEX KEY: 0001849682
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 24793016
MAIL ADDRESS:
STREET 1: C/O CAREDX, INC.
STREET 2: 1 TOWER PLACE, 9TH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-460-8308
MAIL ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
wk-form4_1711585608.xml
FORM 4
X0508
4
2024-03-26
0
0001599298
Summit Therapeutics Inc.
SMMT
0001849682
Dhingra Ankur
C/O SUMMIT THERAPEUTICS INC.
2882 SAND HILL ROAD, SUITE 106
MENLO PARK
CA
94025
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-03-26
4
P
0
100000
3.75
A
354958
I
By Dhingra Family Revocable Trust
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Ankur Dhingra
2024-03-27